Tissue Diagnosis of Hepatocellular Carcinoma

Journal of Clinical and Experimental Hepatology

Volumn 4, Issue , 2014, Pages S67-S73

  Jain, Deepali ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

HCC; Pathology; Tissue diagnosis

Indexed keywords

ASPIRATION CYTOLOGY; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CANCER PROGNOSIS; CLEAR CELL CARCINOMA; FATTY LIVER; FIBROLAMELLAR HEPATOCELLULAR CARCINOMA; FINE NEEDLE ASPIRATION BIOPSY; GLYCOGENOTIC HEPATOCELLULAR CARCINOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PEDUNCULATED HEPATOCELLULAR CARCINOMA; PRIORITY JOURNAL; PSEUDOGLANDULAR HEPATOCELLULAR CARCINOMA; REVIEW; TUMOR DIFFERENTIATION; TUMOR SEEDING; TUMOR VOLUME;

EID: 84954196911     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2014.03.047     Document Type: Review

References (62)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. El-Serag H.B. Hepatocellular carcinoma. N Engl J Med 2011, 365:1118-1127.
3. Nayak N.C., Jain D. End stage chronic Liver Disease - Yesterday, Today and Tomorrow. Liver Cirrhosis: Causes Diagnosis and Treatment 2011, Nova Publishers, Inc, New York, USA.
4. Nayak N.C., Jain D., Vasdev N., Gulwani H., Saigal S., Soin A. Etiologic types of end-stage chronic liver disease in adults: analysis of prevalence and their temporal changes from a study on native liver explants. Eur J Gastroenterol Hepatol 2012 Oct, 24(10):1199-1208.
5. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 2010, 30:3-16.
6. Marrero J.A., Fontana R.J., Fu S., Conjeevaram H.S., Su G.L., Lok A.S. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005, 42:218-224.
7. El-Serag H.B., Tran T., Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-468.
8. Jain D., Nayak N.C., Saigal S. Hepatocellular carcinoma arising in association with von-Meyenburg's complexes: an incidental finding or precursor lesions? A clinicopatholigic study of 4 cases. Ann Diagn Pathol 2010 Oct, 14(5):317-320.
9. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73. REVEAL-HBV Study Group.
10. Yu N.C., Chaudhari V., Raman S.S., et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol 2011, 9:161-167.
11. Chen J.G., Parkin D.M., Chen Q.G., et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 2003, 10:204-209.
12. Bruix J., Sherman M. Practice guidelines committee, American Association for the Study of Liver Diseases: management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
13. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference - European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.
14. Levy I., Greig P.D., Gallinger S., Langer B., Sherman M. Resection of hepatocellular carcinoma without preoperative tumor biopsy. Ann Surg 2001, 234:206-209.
15. Jeong Y.Y., Mitchell D.G., Kamishima T. Small (<20 mm) enhancing hepatic nodules seen on arterial phase MR imaging of the cirrhotic liver: clinical implications. AJR Am J Roentgenol 2002, 178:1327-1334.
16. Sangiovanni A., Manini M.A., Iavarone M., et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010, 59:638-644.
17. Leoni S., Piscaglia F., Golfieri R., et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 2010, 105:599-609.
18. Poon D., Anderson B.O., Chen L.T., et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009, 10:1111-1118.
19. Wang P., Meng Z.Q., Chen Z., et al. Diagnostic value and complications of fine needle aspiration for primary liver cancer and its influence on the treatment outcome. A study based on 3011 patients in China. Eur J Surg Oncol 2008, 34:541-546.
20. Torzilli G., Minagawa M., Takayama T., et al. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 1999, 30:889-893.
21. Stigliano R., Marelli L., Yu D., et al. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 2007, 33:437-447.
22. de Boer W.B., Segal A., Frost F.A., Sterrett G.F. Cytodiagnosis of well differentiated hepatocellular carcinoma: can indeterminate diagnoses be reduced?. Cancer 1999, 87:270-277.
23. Wee A. Fine needle aspiration biopsy of hepatocellular carcinoma and hepatocellular nodular lesions: role, controversies and approach to diagnosis. Cytopathology 2011 Oct, 22(5):287-305.
24. Kuo F.Y., Chen W.J., Lu S.N., Wang J.H., Eng H.L. Fine needle aspiration cytodiagnosis of liver tumors. Acta Cytol 2004, 48:142-148.
25. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2010, 000:1-35. Available at:. http://publish.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpdate2010.pdf.
26. Caturelli E., Bisceglia M., Fusilli S., Squillante M.M., Castelvetere M., Siena D.A. Cytological vs microhistological diagnosis of hepatocellular carcinoma: comparative accuracies in the same fine-needle biopsy specimen. Dig Dis Sci 1996, 41:2326-2331.
27. Caturelli E., Solmi L., Anti M., et al. Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut 2004, 53:1356-1362.
28. Müllhaupt B., Durand F., Roskams T., Dutkowski P., Heim M. Is tumor biopsy necessary?. Liver Transpl 2011 Oct, 17(suppl 2):S14-S25.
29. Cochand-Priollet B., Chagnon S., Ferrand J., Blery M., Hoang C., Galian A. Comparison of cytologic examination of smears and histologic examination of tissue cores obtained by fine needle aspiration biopsy of the liver. Acta Cytol 1987, 31(4):476-480.
30. Tsai Y.Y., Lu S.N., Changchien C.S., et al. Combined cytologic and histologic diagnosis of liver tumors via one-shot aspiration. Hepatogastroenterology 2002, 49(45):644-647.
31. Silva M.A., Hegab B., Hyde C., Guo B., Buckels J.A., Mirza D.F. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008, 57:1592-1596.
32. Durand F., Regimbeau J.M., Belghiti J., et al. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 2001, 35:254-258.
33. Takamori R., Wong L.L., Dang C., Wong L. Needle-tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary?. Liver Transpl 2000, 6:67-72.
34. Chang S., Kim S.H., Lim H.K., et al. Needle tract implantation after sonographically guided percutaneous biopsy of hepatocellular carcinoma: evaluation of doubling time, frequency, and features on CT. AJR Am J Roentgenol 2005, 185:400-405.
35. Durand F., Belghiti J., Paradis V. Liver transplantation for hepatocellular carcinoma:role of biopsy. Liver Transpl 2007, 13:S17-S23.
36. Maturen K.E., Nghiem H.V., Marrero J.A., et al. Lack of tumor seeding of hepatocellular carcinoma after percutaneous needle biopsy using coaxial cutting needle technique. AJR Am J Roentgenol 2006, 187:1184-1187.
37. Llovet J.M., Vilana R., Bru C., et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001, 33:1124-1129.
38. Goodman Z.D., Terraciano L.M. Tumours and tumour-like lesions of the liver. MacSween's Pathology of the Liver 2007, 761-814. Churchill Livingstone, Philadelphia, PA. 5th ed. A.D. Burt, B.C. Portmann, L.D. Ferrell (Eds.).
39. Ishak K.G., Goodman Z.D., Stocker J.T. Tumors of the Liver and Intrahepatic Bile Ducts. Atlas of Tumor Pathology. 3rd Series. Fascicle 31 2001, Armed Forces Institute of Pathology, Washington, DC.
40. Minervini M.I., Demetris A.J., Lee R.G., Carr B.I., Madariaga J., Nalesnik M.A. Utilization of hepatocyte-specifi c antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol 1997, 10(7):686-692.
41. Kakar S., Gown A.M., Goodman Z.D., Ferrell L.D. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med 2007, 131(11):1648-1654.
42. Nakashima O., Sugihara S., Kage M., Kojiro M. Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins. Hepatology 1995, 22(1):101-105.
43. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009, 49(2):658-664. International Consensus Group for Hepatocellular Neoplasia.
44. Di Tommaso L., Franchi G., Park Y.N., et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007, 45:725-734.
45. Timek D.T., Shi J., Liu H., Lin F. Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens. Am J Clin Pathol 2012 Aug, 138(2):203-210.
46. Fujiwara M., Kwok S., Yano H., Pai R.K. Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies. Cancer Cytopathol 2012 Aug 25, 120(4):230-237.
47. Kong C., Appenzeller M., Ferrell L. Utility of CD34 reactivity in evaluating focal nodular hepatocellular lesions sampled by fine needle aspiration biopsy. Acta Cytol 2000, 44:218-222.
48. Jain D. Sal-like protein 4: an epithelial and germ cell marker. Hum Pathol 2013 Jul, 44(7):1453.
49. Oikawa T., Kamiya A., Zeniya M., et al. Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology 2013 Apr, 57(4):1469-1483.
50. Yong K.J., Gao C., Lim J.S., et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 2013 Jun 13, 368(24):2266-2276.
51. Hirohashi S., Ishak K.G., Kojiro M., et al. Hepatocellular carcinoma. Tumors of the Digestive System 2000, 159-172. IARC Press, Lyon, World Health Organization Classification of Tumors. S.R. Hamilton, L.A. Aaltonen (Eds.).
52. Jakate S., Yabes A., Giusto D., et al. Diffuse cirrhosis-like hepatocellular carcinoma: a clinically and radiographically undetected variant mimicking cirrhosis. Am J Surg Pathol 2010, 34:935-941.
53. Jarnagin W.R., Weber S., Tickoo S.K., et al. Combined hepatocellular and cholangiocarcinoma. Demographic, clinical, and prognostic factors. Cancer 2002, 94:2040-2046.
54. Kim H., Choi G.H., Na D.C., et al. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. Hepatology 2011, 54:1707-1717.
55. Durnez A., Verslype C., Nevens F., et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006, 49(2):138-151.
56. Yeh C.N., Lee W.C., Jeng L.B., Chen M.F. Pedunculated hepatocellular carcinoma: clinicopathologic study of 18 surgically resected cases. World J Surg 2002, 26:1133-1138.
57. Shiina S. Image-guided percutaneous ablation therapies for hepatocellular carcinoma. J Gastroenterol 2009, 44(suppl 19):122-131.
58. Callea F., Giovannoni I., Stefanelli M., Villanacci V., Lorini G., Francalanci P. Glycogenotic hepatocellular carcinoma with glycogen-ground-glass hepatocytes: histological, histochemical and microbiochemical characterization of the novel variant. Histopathology 2012 May, 60(6):1010-1012.
59. Salomao M., Yu W.M., Brown R.S., Emond J.C., Lefkowitch J.H. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 2010, 34:1630-1636.
60. Jain D., Nayak N.C., Saigal S. Hepatocellular carcinoma in nonalcoholic fatty liver cirrhosis and alcoholic cirrhosis: risk factor analysis in liver transplant recipients. Eur J Gastroenterol Hepatol 2012 Jul, 24(7):840-848.
61. Jain D., Nayak N.C., Kumaran V., Saigal S. Steatohepatitic hepatocellular carcinoma, a morphologic indicator of associated metabolic risk factors. A Study from India. Arch Pathol Lab Med 2013 Jul, 137(7):961-966.
62. Jain D. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 2012 May, 43(5):769-770.